

Article

Short-term *ex vivo* culture of CTCs from advance breast cancer patients: clinical implications.

Nuria Carmona-Ule¹, Miriam González-Conde^{1,3}, Carmen Abuín¹, Juan Cueva^{2,3}, Patricia Palacios^{2,3}, Rafael López-López^{1,3}, Clotilde Costa^{1,3,*} and Ana Belén Dávila-Ibáñez^{1,*}

¹ Roche-Chus Joint Unit, Translational Medical Oncology Group, Oncomet, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, 15706 Santiago de Compostela, Spain. Nuria.carmona.ule@sergas.es, Miriam.gonzalez.conde@sergas.es, Carmen.abuin.redondo@sergas.es

² Medical Oncology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain. Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain. jfcueva@gmail.com, patricia.palacios.ozores@sergas.es, Rafael.lopez.lopez@sergas.es

³ CIBERONC, Centro de Investigación Biomédica en Red Cáncer, 28029 Madrid, Spain.

* Correspondence: ana.belen.davila.ibanez@sergas.es

clotilde.costa.nogueira@sergas.es

Tel.: +34-981-955-602

Simple Summary: Circulating tumor cells (CTCs) are responsible for metastasis, they represent tumor biology and have also predictive value for therapy monitoring and prognosis of metastatic breast cancer patients. In the blood, CTCs are found in low frequency and a small percentage of them survive. Therefore, achieving their expansion *in vitro* will allow performing characterization and functional analysis. In this work, we used growth factors and Nanoemulsions to support CTCs culture. We have seen that the CTCs subpopulation capable of *ex vivo* expanding presented mesenchymal and stem characteristics and loss of epithelial markers. Besides, CTC culture predicted progression-free survival while CTC account did not in this patient's cohort.


Abstract

Background: Circulating tumor cells (CTC) have relevance as prognostic markers in breast cancer. However, the functional properties of CTCs or their molecular characterization have not been well-studied. Experimental models indicate that only a few cells can survive in the circulation and eventually metastasize. Thus, it is essential to identify these surviving cells capable of forming such metastases. **Methods:** We isolated viable CTCs from 50 peripheral blood samples obtained from 35 patients with advanced metastatic breast cancer using RosetteSep™ for *ex vivo* culture. The CTCs were seeded and monitored on plates under low adherence conditions and with media supplemented with growth factors and Nanoemulsions. Phenotypic analysis was performed by immunofluorescence and gene expression analysis using RT-PCR and CTCs counting by Cellsearch® system. **Results:** We found that in 75% of samples the CTC cultures lasted more than 23 days, predicting a shorter Progression-Free Survival in these

patients, independently of having ≥ 5 CTC by Cellsearch®. We also observed that CTCs before and after culture showed a different gene expression profile. **Conclusions:** the cultivability of CTCs is a predictive factor. Furthermore, the subset of cells capable of growing *ex vivo* show stem or mesenchymal features and may represent the CTC population with metastatic potential *in vivo*.

Keywords: CTC, cell culture, liquid biopsy, breast cancer

Graphical Abstract



1. Introduction

During 2020 breast cancer was the most commonly diagnosed cancer, with an estimated 2.3 million new cases[1]. Metastasis is the leading cause of death in breast cancer patients, mainly conditioned by resistance to therapy and tumor heterogeneity [2]. The circulating tumor cells (CTCs) are those cells that abandon the primary tumor and circulate through the vascular system to eventually colonize distant organs and originate the formation of metastasis[3]. High CTC numbers have been linked with worse outcome in prostate, colon and breast cancer metastatic patients [4–6] and CTC number increase over time indicates therapy failure [7]. However, CTC count does not allow therapeutic intervention. Therefore, CTC expansion *in vitro* would permit their downstream analysis, evaluate personalized cancer therapies and drug sensitivity testing[8,9]. Even though CTCs are a highly valuable source of tumor material, their molecular analysis is still challenging due to their rarity, as they are as infrequent as < 20 CTCs from 10 mL of blood[10]. Additionally, most of the CTC population dies in the bloodstream due to shear stress or immune surveillance[11]. CTCs isolated show reduced proliferation–hindering their *ex vivo* expansion [12]. Thus, nowadays CTC growth *ex vivo* is still one of the main challenges in the field, mostly due to CTC extreme rarity, fragility, and phenotypic heterogeneity.

Despite its obvious complexity, different cultures of CTCs have already been established. Thus, the first CTCs primary culture was established in 2013 from advanced breast cancer patients using CTCs negative for the epithelial marker EpCAM[13]. Later, in 2015, Cayrefourcq *et al.* established different cultures and a permanent cell line from CTCs isolated from a metastatic colon cancer patient, who presented a high number of CTCs (≥ 300 CTC)[14]. Currently, it is established that for long-term CTC cultures success, a high number of CTCs is required [15]. Numerous attempts have been made to culture CTCs from patient blood samples, however, the success rates of *in vitro* CTC cultures is around 6–20% [16]. To date, only a few short-term CTCs cultures, from 3 days to 14 but also up to 40 days, have been reported for different cancers [14][17–26], and specifically for breast cancer[16,27,28]. Nonetheless, the establishment of long-term CTC cultures has proven to be even more challenging for breast[13,28,29] and other tumor types[30–32], being of much lower successful.

Ex vivo tumor cell culture is usually performed in 2D cultures however the cell morphology or cell-cell and spatial interactions are lost [33]. Since it has been demonstrated the importance of these interactions in different cellular functions as proliferation or cell differentiation[34], 2D cultures show a considerable drawback. Furthermore, in 2D cultures nutrients or oxygen accessibility is unlimited[35], thus, this situation do not fully represents the setting in the tumor mass *in vivo*[36]. However, 3D cultures appears as a solution to overcome these limitations, simulating the environment of tumor cells, in which cell-cell and cell-environment interactions are maintained, as well as cell polarity and morphology[37][22]. Precisely, a non-adhesive substrate is employed to culture cancer stem-like cells (CSC) from primary tumors creating a multi-layered cell cluster[38,39]. Thus, for *ex vivo* CTC expansion, ultra-low attachment plates are frequently used[28,40–42]. Besides, hypoxic conditions (1–2% O₂) can promote cellular reprogramming towards a CSC phenotype [43]. *In vivo*, tumor cells are supplied with growth factors, hormones, lipids and other metabolites from serum. Nonetheless, standard culture media are devoid of them, although are essential for the CTC culture *ex vivo*[44]. Thus, the majority of protocols for CTC culture employ supplemented media to provide all the necessary nutrients for these rare cells[28,31].

In this regard, we have recently published a protocol that uses Nanoemulsions (NEs) formulated from lipids and fatty acid to promote the proliferation of breast cancer cell lines and CTCs from a mouse model derived from breast cancer cell line [45]. Our study was based on previous studies that reported how mitochondrial metabolism (including oxidation of glutamine and fatty acids) or the accumulation of lipids and free fatty acids is linked to invasion, aggressiveness, migration, and progression of breast cancer[46–48].

However, there is still the need of knowledge to know the optimal conditions that influence the success of CTC cultures and which are the CTCs populations capable of surviving *in vitro*. Therefore, to shed light on this field of research, we carried out a functional study of CTCs isolated from patients with metastatic breast cancer (mBC), placing them in culture and monitoring them over time. As a novelty, we used a culture protocol in which, together with growth factors, NEs (lipids and fatty acids) are added to the culture medium to stimulate the metabolism of CTCs.

2. Materials and Methods

2.1. Patients

This study was approved by the local ethics committee (Ethics Committee of Galicia approval reference number 2015/772) and all patients gave written informed consent. All samples were anonymized and encoded before the analysis.

Inclusion criteria: women, advanced breast cancer, any subtype, age \geq 18 years. Exclusion criteria: known diagnosis of psychiatric illness that prevents the patient from understanding and accepting the conditions of the study, current of malignant tumor in the last 5 years, except for basal cell carcinoma, squamous cell carcinoma or carcinoma *in situ* of the cervix properly treated. The patient's characteristics are described in section 3.1 and Table 1.

2.2. CTC isolation and *ex vivo* culture

Two EDTA-coated vacutainer tubes (Becton Dickinson) of 7.5 ml of peripheral blood were collected per patient at different time points. Blood samples were processed within two hours after withdrawal. CTC isolation was performed using the label-independent antibody cocktail RosetteSepTM CTC Enrichment Cocktail Containing Anti-CD56 (STEMCELL Technologies). Enriched cells isolated with RosetteSepTM from the 1st EDTA tube were used for CTC culture as described below. In some random samples, the 2nd EDTA tube was processed for CTC enrichment by RosetteSepTM, placed in RNAlaterTM Solution (Invitrogen, ThermoFisher Scientific) and kept at -80°C until further gene expression analyses. Besides, the Peripheral Blood Mononuclear cells (PBMCs) of some patients were isolated from one 7.5 mL EDTA tube of peripheral blood by density gradient centrifugation protocol (LymphoprepTM, STEMCELL Technologies) in SepMateTM tubes (STEMCELL Technologies) according to manufacturer's instructions, for *ex vivo* culture, RNAlater storage and subsequent gene expression analysis.

Cell pellet from the previous step was resuspended in 200 μ L of supplemented MammoCultTM Human Medium Kit (STEMCELL Technologies). This supplemented medium contained 0.4 μ g/mL progesterone (Sigma-Aldrich), 0.4 μ g/mL β -estradiol (Sigma-Aldrich), 4 μ g/mL heparin (STEMCELL Technologies), 0.48 μ g/mL hydrocortisone (STEMCELLTM), 5% (v/v) UltraGROTM (AventaCell BioMedical Co.), 4% (v/v) B-27 Supplement (50X) (Gibco), 20ng/mL recombinant basic Fibroblast Growth Factor (bFGF) (Gibco), 20ng/mL recombinant Epidermal Growth Factor (EGF) (Sino Biological), and 1% (v/v) penicillin/streptomycin (Sigma-Aldrich). The cell suspension was seeded initially in one well of an Ultra-Low-Attachment 96-well plate (Corning) and cultured using hypoxic conditions (37°C, 1-2%O₂) for 1 week. Cell cultures were supplemented with fresh medium every 2

days with minimal well disturbance to avoid cell loss. NEs were prepared as previously described[45], and were added to the media every two days at the same time as the fresh medium supplement. Before addition to the media, NEs were filtered using Acrodisc® PFS Syringe filters and mix with cell medium (concentration ranges were within 6.7×10^8 particle/mL to 2.14×10^9 particle/mL). After 1 week of cell culture, cells were switched to standard cell culture conditions (37°C , 5% CO_2). When 85% confluence was reached, growing cells were transferred to an ultra-low attachment 24-well plate (Corning) and subsequently to Ultra low attachment 25cm² Flasks (Corning) at 90 % of confluence. Cultures were maintained up to the entrance to the decline phase (live cells declined as cell death predominated in the culture). Samples for IF and RNA isolation were taken between 10-15 days after seeding.

2.2. CTC enumeration

In 34 samples, one 10 mL CellSave Preservative tube (Menarini-Silicon Biosystems) was collected in parallel to EDTA tubes and processed for CTC enumeration by the CellSearch® System, using CellSearch® Epithelial Circulating Tumor Cell Kit (Menarini, Silicon Biosystems Inc, Bologna, Italy). EpCAM-positive enriched cells were labelled with phycoerythrin-conjugated anti-cytokeratins (8, 18, and 19) antibodies, allophycocyanin-conjugated anti-CD45 antibodies, and 4,6-diamino-2-phenylindole (DAPI). The CellTracks Analyzer (Menarini-Silicon Biosystems, Bologna, Italy) was used to acquire digital images of the 3 different fluorescent dyes, which were reviewed by trained operators to determine the CTCs count.

2.3. Immunofluorescence staining, Fluorescence Microscopy and Confocal Microscopy Analysis

Cells from 3D culture were washed with dPBS (Lonza) (centrifugation at 500xg, 5min, 20°C) and fixed with cold 4% paraformaldehyde (PFA) (ThermoFisher) for 15 min. Then, cells were washed with dPBS (Lonza) (centrifugation at 500xg, 5min, 20°C). Afterward, cell solutions were immunostained using a combination of epithelial antibodies: Cytokeratin Pan Antibody (1:50, AlexaFluor-488 anti-human, Clone AE1/AE3, eBioscience-Invitrogen), EpCAM Antibody (1:25, AlexaFluor-488 anti-human, Clone 9C4, Biolegend), E-CADH Antibody (1:25, FITC anti-human CD324, Clone 67A4, Biolegend); Vimentin Antibody (1:200, Alexa®-647 anti-human, Clone D21H3, CellSignaling Technology), and CD45 Antibody (1:30, PE anti-human, Clone MEM-28, ExBio). NucBlue™ (Hoechst 33342 dye, ThermoFisher) was used to counterstain nuclei. InsidePerm Buffer (Inside Stain Kit, Miltenyi Biotec) was used as antibody diluent.

Stained solutions were examined by (i) confocal microscope (Leica TSC SP5 X, Leica Microsystems) and (ii) fluorescence microscope (Leica DMi8 automated Microscope, Leica Microsystems). In both microscopes, 63X oil immersion objective was used. Images were used for the morphometric analysis using ImageJ software[49], following previously described parameters[50].

2.4. RNA extraction and gene expression analysis

AllPrep DNA/RNA Mini Kit (QIAGEN) was used for RNA extraction (CTCs and PBMCs), following the manufacturer's protocol. 11 μL of total RNA were retrotranscribed into cDNA with SuperScript III (ThermoFisher Scientific). Samples were preamplified with Taqman Preamp Master Mix (ThermoFisher Scientific). Gene expression analysis for a custom panel of 20 genes (Table S1) was performed with probes and Master Mix TaqMan (Applied Biosystems) on a LightCycler 480 II (Roche Diagnostics). The relative expression was calculated considering B2M as a reference gene. To clarify the visualization of the heatmap, relative expression was codified from 0 to 7 points, being 0 no gene amplification.

2.5. Statistical analysis.

Statistical analysis was performed using GraphPad Prism 6.01 software (GraphPad Software Inc.) and R Studio Version R-3.6.3. ClustVis tool was used for heatmap and PCA performance. Fisher exact test and Chi-square test were used for association analysis. We used the Wilcoxon signed-rank test for media comparisons (CTC enumeration between groups and gene expression comparison before and after culture using paired test). Progression-free survival (PFS) and overall survival (OS) were visualized using Kaplan-Meier plots and tested by the log-rank test. Only p values < 0.05 were considered statistically significant.

3. Results

3.1. Patient's and samples characteristics

A total of 50 samples from 35 metastatic Breast Cancer (mBC) patients were included in this study. Patients were enrolled from October 2017 to December 2020 and the end of follow-up was February 2021. Patient characteristics are shown in Table 1. The median age was 57.14 (range, 32-82 years). The molecular subtypes were Her2 enriched (n=4), Luminal (n=22) and Triple-negative (n=9). All patients were stage IV and 88.57 % had ≥ 2 metastatic locations. Also, 23 out of 35 had bone and visceral metastasis (65.71 %), 3 out of 35 (5.57 %) had only bone metastasis while 9 out of 35 (25.71 %) presented visceral metastasis alone. Median PFS and OS were 6.3 and 10 months respectively considering the time of sample collection as the starting point. Regarding longitudinal samples, they were collected at different time points through the disease. Thus, 32 samples out of 50 (64%) were collected after the start of therapy. The remaining 36% were collected at baseline (diagnosis of metastasis). Of the treated patient samples, 14 were first-line and 18 had two or more lines of treatment (Figure S1). The treatments corresponding to the 35 patients were chemotherapy (71.43 %), endocrine therapy plus CDK4/6 inhibitors (17.14 %) or others as endocrine therapy alone or anti-Her2 therapies.

Table 1. Clinic-pathologic characteristics of the cohort of metastatic breast cancer patients (n=35).

Category	n	%
Age		
≤ 57	18	51.43
> 57	17	48.57
Tumour stage		
IV	35	100
ER status		
Positive	21	60
Negative	12	34.29
PR status		
Positive	15	42.86
Negative	18	51.43
HER2 status		
Positive	8	22.86
Negative	26	74.29
Metastasis location		
Bone	26	74.29
Visceral	32	91.43
Bone & Visceral	23	65.71
Number of metastatic sites		
1	4	11.43
2	13	37.14
≥ 3	18	51.43
Therapy		
Chemotherapy	25	71.42
CDKi+ET	6	17.14
Others	4	11.42
Progression	31	88.57
Exitus	24	68.57

3.2. CTC short-term culture from metastatic Breast Cancer patients

3.2.1. CTC culture characterization

CTCs isolated using a negative enrichment approach (RosetteSep™), were plated under non-adherent conditions, in MammoCult media supplemented with growth factors plus NEs and under hypoxic conditions (for the first seven days) (see M&M). Figure 1 presents the schematic followed workflow in this study. Of the 50 initial samples, the follow-up was carried out in 48 of them, with a mean time of 56.35 days (range, 8-291 days). The criteria to consider the endpoint of the culture was cell density reduction or the presence of apoptotic cells. Previous publication of short-term culture, described maintenance of CTCs cultures *ex vivo* between 3 and 14 days [31][28]. Considering the median progression time (100 days) and the days of CTCs in culture, we performed a ROC curve analysis for these samples. The best threshold able to discriminate both groups was 23.5 days (AUC=0.65). Therefore, we have considered the cut-off of 23 days as a successful CTC culture. Using this criterion, short-term cultures were successfully propagated in 36 samples

(75%). In 6 of them, the follow-up was stopped due to culture contamination. Those samples in which this occurred before day 23rd (n=2), were considered failure culture.




Figure 1. Schematic Workflow of CTCs samples isolation, culture and analyses. (1) Methodology followed for the isolation and *ex vivo* cell culture of CTCs from mBC patients. Cells were isolated using: CellSearch® System (determination of EpCAM⁺ cells) and RosetteSep™ (enrichment of CTCs for cell culture). Cells were cultured under ultra-low attachment plates to support 3D culture and every two days cells were supplemented with fresh supplemented medium and NEs. (2) Immunofluorescence characterization by Confocal microscopy and Fluorescence microscopy of cell cultures. (3) Gene Expression Analysis was performed using paired samples before and after cell culture. (4) Survival Analysis was carried out to determine the relation between time (days) of culture or presence of Red Blood Cells (RBCs) as a predictive factor in the patient's outcome.

Since cells were grown on ultra-low attachment plates, the majority tended to grow in suspension. Interestingly, some samples presented cells growing both in suspension and adherence (Figure 2A).

In 34 samples from 28 patients, paired CTC enumeration was performed by Cellsearch® system at the time of the start of culture. Fifty three per cent of the samples showed ≥ 5 CTCs (range 0-1,000 CTCs) although only 4 of them had ≥ 350 CTCs. No association was observed between culture successes and having ≥ 5 CTC (pre-established cut-off in mBC). The highest CTCs count was observed in the successful or positive culture group (Figure 2B), however, there were no significant differences in the mean CTCs numbers in both groups.



A**Susp.****Susp. and Adh.****B**

Figure 2. A) Representative image of cultured CTCs in ultra-low attachment 96-well plates. It was observed two growth behaviours: i) cells that grow in suspension (left panel); ii) cells growing in suspension co-existing with adherent cells (right panel). Blue arrows represent cells in suspension while orange arrows cells growing in adherence. The scales bar represent 75 μ m. (B) Number of CTCs measured by CellSearch® respect to their ability to establish a successful culture in 34 metastatic breast cancer samples. Negative culture, in blue (n=11) and positive culture (n=25), in red.

After ~2 weeks in culture, it was performed a phenotypic characterization in some random samples. For that, we carried out a triple immunofluorescence assay for epithelial (E-Cad, EpCAM and PanCK), (Figure 3), mesenchymal (Vimentin) and white blood cells markers (CD45). Epithelial features were observed in a low percentage of samples (18.18 %) (n=22) while 47% showed vimentin-positive cells (n=17), or none marker but nucleus in scarce samples. Of the analyzed samples by immunofluorescence, only 4 did not result in a culture-positive although none of them showed positive marker expression by immunofluorescence. We also detected CD45+ cells co-inhabiting in the culture in the majority of the samples. As expected, the presence of cell clusters (≥ 2) was observed in 70.58 % of samples (n=17) (Figure 3). In another vein, Cellsearch® data (before culture) did not associate with the expression of epithelial markers after culture.




Figure 3. Representative images by confocal microscopy of Immunofluorescence (IF) characterization of CTCs after culture: single CTCs, CTC cluster, Vimentin⁺ (VIM⁺) cluster, VIM⁺-CD45⁺ cells and CD45⁺ cells. Immunofluorescent staining was performed using a combination of anti-human Epithelial markers (Epith: EpCAM, E-Cadh, and PancK) (in green), anti-VIM (in yellow), and anti-CD45 (in red). Scale bar represents 25 μ m.

Since some cells did not meet the standardized CTC criteria (CK +; CD45-; DAPI +), we performed a morphometric analysis of some of the immunofluorescence images (n=82 from 18 patients). Although there are no standardized data, different research groups had reported that CTCs exhibit a larger nucleus size ($> 9\mu\text{m}$) and nucleus/cytoplasm ratio (> 0.8) [50]. We observed that the nucleus from cells with epithelial markers, VIM or absence of any marker are larger than those cells CD45-positive (mean 12.97 vs 10.27 μm , $p = 0.008$). Furthermore, considering both nucleus size ($> 9\mu\text{m}$) and the nucleus/cytoplasm ratio >0.8 , CD45 negative cells meet the criterion preferentially ($p = 0.02$).

In 70.9 % of samples, it was observed contamination with RBCs in the culture that eventually disappeared. The presence of RBCs did not associate with culture success nor with CTC account. Besides, the success of the culture did not show an association with the molecular subtype, the age of the patient, the therapy received or the visit in which the sample was collected (before or after therapy initiation; first line or ≥ 2 lines of treatment).

3.2.2. Gene expression analysis of paired samples before and after culture.

Next, we performed a gene expression analysis for a panel of 20 genes before and after culture (~2 weeks) in a small set of samples. All of them were in culture for more than 23 days. The genes selected included epithelial (*KRT5*, *CDH1*, *EpCAM*), mesenchymal (*VIM*, *SNAI1*, *TWIST*), stem (*ALDH1A1*, *PROM1*), breast specific (*ESR1*, *PALB2*) and other genes related to cell cycle or other cancer pathways (*CCND1*, *CTNNB1*, *Ki67*, etc).

CTCs before and after culture shown a differential gene expression pattern as depicted in the Principal Component Analysis diagram and hierarchical clustering, which grouped the samples based on whether they had been in culture or not (Figure 4A-B). Remarkably, epithelial markers are detected preferentially in the CTCs freshly isolated from the blood, which have not been cultured. Breast specific markers as *PALB2* or *ESR1* are expressed independently of the culture state, although both genes showed a higher relative expression in CTCs from cultured samples ($p=0.03$ and 0.06 respectively) suggesting that mammary tumor cells are proliferating in the culture. The mesenchymal gene *VIM* was found in all the samples before and after culture, *TWIST* expression appeared only after culture in 2 out of 6 samples while *SNAI1* is lost. *VIM* was overexpressed in 4 out of 6 samples after culture. One of the samples, after culture, showed less *VIM* expression and an increase in *CDH1*, which indicates a maintenance of epithelial features. *CD45* relative expression showed a slight drop after culture.




Figure 4. CTC gene expression analysis of 6 patients before (BC) and after (AC) culture. Of these samples, 4 of them were not included in the previous immunofluorescence characterization. 5 samples were collected after therapy initiation. A) Clustered heatmap depicting CTCs gene expression levels of the listed genes. Light red indicates no expression. Relative gene expression (to B2M) was ranged and coded from 1 to 7 (dark red). B) Principal component analysis using gene expression of the listed genes (see Heatmap).

Taking into account that the isolation method used is not characterized by its purity, non-tumor cells may be contaminating the culture. This can be influencing the gene expression analysis of cells after culture, analyzed as a pool.

For this reason, in 4 of the 6 samples, we analysed the expression of PBMCs before and after culture (cultured under the same conditions that the CTC- enriched fraction).

CTCs after culture exhibited a differential expression profile, ruling out that gene expression is influenced by non-specific cells that accompany the culture of CTCs (Figure S2A-B).

In addition, other EMT related genes were analyzed. Thereby, *CTNNB1* and *GDF15* showed higher relative gene expression after culture ($p=0.03$ and 0.06 , respectively). This is in agreement with previous findings in which mesenchymal markers were mainly observed after culture. Also, *CCND1* showed an increase but is not significant. Notably, the expression of *CD36* and *ALDH1A1* was detected in all CTC samples (before and after culture) and it is significantly elevated in cultured samples ($p=0.03$) (Figure S2C-D). Since *CD36* is a marker associated with certain cells of the myeloid lineage we checked whether *CD36* expression could come from PBMCs present in the culture. For that, we compared the relative expression of CTC and PBMCs after and before culture. We observed a notable overexpression in CTCs after culture ($p=0.002$) while PBMCs after culture just showed a slight increase ($p=0.64$) (Figure S2E), reinforcing that the expression of *CD36* comes from CTCs.

In summary, CTCs after culture showed mesenchymal and stem cell features together with breast specific markers. Besides, their genetic profile differs from culture paired PBMCs, reinforcing the tumoral origin of culture cells.

3.3. CTC cultivability for more than 23 days predicts the patient's progression.

Last, considering the cultivability (positive or negative based on being > 23 days in culture), we performed survival analysis to determine if the culture time could predict the outcome of the patients. Patients whose samples originated cultures that lasted more than 23 days, considered positive cultures, showed shorter times to progression ($p= 0.008$, log-rank test, 354 vs 84 days; $n=48$), (Figure 5A). If we only consider those samples with paired Cellsearch® data (Figure S1), culture-positive also predicted shorter PFS ($p=0.002$, log-rank test, 365 vs 84 days; $n=32$), (Figure S3A). On contrary, having ≥ 5 CTCs (measured by Cellsearch®) did not predict patients PFS ($p = 0.2$, log-rank test, 147 vs 85.8 days; $n = 32$), (Figure 5B). Besides, a positive culture was also predictive ($p=0.05$, log-rank test, $n=34$), (Figure S3B) when only 1 sample per patient was considered (Figure S1). The culture success was 75 % and 76.47 %, respectively for these last sample's cohorts.

Regarding OS, culture positivity was not a predictive factor in these samples ($p=0.3$, log-rank test, 596 vs 317 days; $n=48$), (Figure 5C), although the mean OS times of both groups were significantly different (592.5 vs 158 days, $p=0.01$). Contrary to PFS analysis, having ≥ 5 CTCs was linked with shorter OS ($p=0.01$, log-rank test, 749 vs 167 days; $n=34$), (Figure 5D).




Figure 5. Kaplan-Meier plots for PFS and OS for: cultivability (Culture negative (black) or positive (red)) (A,C) and CTCs enumeration by Cellsearch® system (≥ 5 CTCs (red) or < 5 CTCs (black)) (B,D). P-values were calculated using the log-rank test.

Interestingly, we found that the presence of RBCs in the culture was linked to a worse patient outcome ($p=0.03$, log-rank test, 443 vs 99 days for PFS and $p=0.04$, log-rank test, 834 vs 454 for OS, $n=31$), (Figure 6A-B). Also, the amount of RBCs in culture tended to correlate with shorter both PFS and OS ($p=0.05$ and 0.03, respectively), (Figure S3E-G). When it is considered only those samples with Cellsearch® data or just one sample per patient, the presence of RBCs in culture is also predictive for PFS ($p=0.01$ and 0.05 respectively), (Figure S3C-D). The same trend is also observed with the amount of RBCs in the culture plate in the aforementioned sample's cohorts (Figure S3G).




Figure 6. Kaplan-Meier plots for PFS (A) and OS (B) for presence of RBCs (red) or absence (black) in the culture. P-values were calculated using the log-rank test.

CTC maintenance in culture for more than 23 days predicted PFS. Besides, the presence of RBCs in the sample also predicted the patient's outcome while Cellsearch® data did not.

4. Discussion

There are multiple publications where the value of CTCs for patient follow-up has been reported, especially concerning the enumeration of CTCs [51,52]. In recent years, progress has also been made in the detection of mutations and phenotypes in CTCs that can be clinically relevant [53,54]. However, there is still a gap to know if CTCs can provide information for routinely clinical decision making, especially for precision medicine. Comprehensive characterization of CTCs in transcriptomic, genomic, and functional terms is difficult mainly due to their low frequency in blood, heterogeneity, poor survivability and challenging methods of CTC isolation. Having CTC lines will be a huge advance to deepen our knowledge in the biology of CTCs and will permit us to perform CTC functional studies, allowing the characterization of those tumor cells responsible for metastasis[55]. Currently, the success to generate stable lines of CTCs is subjected to a high tumor burden[56], which represents a fatal clinical condition for the patient. Thus, CTC culture is one of the present challenges in the liquid biopsy field. To date, few CTCs cell lines have been obtained [11,26–30].

In this work, we have carried out a functional characterization of CTCs, studying their ability to grow in culture, to decipher which are the features that boost their culturability. For that, we choose a negative isolation CTCs enrichment approach, to guarantee minimal cell damage and to obtain a heterogeneous CTC population. The CTCs were cultured under ultra-low attachment conditions using a specific protocol, which includes the addition of NEs as previously described by our group[45]. The addition of biocompatible NEs composed of lipid and fatty acids to support CTC cultures, improving their proliferation capacity, has not been reported to date. The advantage of NEs promoting cell proliferation is supported since it is known that the accumulation of intracellular lipids can contribute to tumor progression and metastasis[57–59]. Thus, the availability of extracellular lipids and fatty acids in the medium might help to activate the metabolism of cultured cancer cells. By employing the aforementioned protocol, we observed that CTCs can grow *ex vivo* for weeks (mean 8 weeks). It was observed a positive culture in 75% of the analysed samples, implying more than 23 days with proliferative and survival features, which is a higher percentage than previously published works which reported 13 or 28 % of success [60,61]. Cultured CTCs showed a specific phenotype with low

epithelial markers and the presence of mesenchymal markers such as vimentin. This is in agreement with different published studies that indicate that after 14 days in culture, CTCs lost their epithelial features[62][27] and exhibited mesenchymal marker[25][63]. Thereby, Khoo *et al.* maintained CTC cultures for 2-8 weeks and observed that CTC in culture over time presented more mesenchymal characteristics, with an increase in Vimentin and Fascin staining and almost a complete loss of epithelial characteristics. They also observed that some CK+ cells presented vimentin expression, suggesting the presence of intermediate phenotypes[27].

Previous works have reported how CTCs in the blood circulation suffered from fluid shear stress, promoting EMT phenotype and maintained pre-existing mesenchymal cells[64]. Hence, most tumor cells released into circulation can be eliminated by fluid shear stress and if so, those CTCs capable of surviving and resisting fluid shear stress should be the subpopulations capable of generating metastatic tumors *in vivo* or cultures of CTCs *in vitro*. Accordingly, due to the CTCs culture conditions, as non-adherent conditions, we are boosting the survival of CTCs stem-like phenotype.

Interestingly, in our cultures, we found expression of *GDF15* and *CTNNB1*, both genes related to EMT and stemness. On one hand, *GDF15*, a member of the TGF- β superfamily, has been linked with macrophages, adipocytes, and several carcinomas including breast cancer. *GDF15* plays a dual role in the evolution of cancer[65]. Thus, under normal physiological conditions, inhibits early tumor promotion. However, its abnormal expression in advanced cancers causes proliferation, angiogenesis, invasion, metastasis, drug resistance, stemness or immune escape[66]. On the other hand, *CTNNB1*, which encodes beta-catenin, has been linked to the EMT process, CSC pluripotency, and cancer signalling [67]. Besides, it has been seen that overexpression of *CTNNB1* in CTCs has prognostic value in both cancers, melanoma[68] and pancreatic[69]. Additionally, *ALDH1A1*, a stem cell marker linked with mammary stemness[63] was also increased after culture. This is in agreement with Zhang and colleagues who established long-term culture from CTCs *ALDH1A1(+)*; *EpCAM(-)* in breast cancer suggesting that this CTC population was able to form brain metastasis [13]. It has been reported that EMT induction leads to stem markers expression and increased tumorigenic capacity in mouse models [70,71] and that the EMT program led to a spectrum of cell states with mixed epithelial and mesenchymal characteristics. Importantly, only those cells with the intermediate phenotype and stem feature associates with metastatic spread[72]. This agrees with our data since we saw that the cells that survive in culture show mainly stem or mesenchymal features.

Importantly, genes related to breast cancer, such as *ESR1* or *PALB2* were observed in all the analyzed samples, before and after culture. After culture was detected an increase in their relative expression, pointing that the subset of CTCs growing in culture is mainly of mammary origin. Besides, *PALB2* expression in CTCs was already described and linked with worse outcome in advanced breast cancer patients by our group[73]. Furthermore, we have seen that cells in culture with epithelial characteristics or absence of *CD45* meet the morphometric criteria of CTC described by other authors[50], reinforcing the tumor origin of cells in culture. In recent years, the standard CTC condition has included morphological criteria based on cytopathological [74-78]. It is known that there are distinct subpopulations of CTCs with differential expressions and morphological data. Besides, the conditions in which these parameters are obtained (before or after suspension culture; suspension or adherence; immunofluorescence or immunocytochemistry assay, CTC-isolation approach) can lead to a variety of results. Therefore, there is no universal criterion, although it is clear that cytometric analyses discriminate CTCs from blood cells (monocytes, granulocytes or tumor-associated macrophages)[79].

After culture, we observed a lower expression of *CD45* compared with their counterparts before culture which may indicate that the culture favours tumor cells growth. CTCs before culture seem to show higher contamination of *CD45+*

cells, as supported by the hierarchical clustering which groups these samples interspersed with PBMCs while CTCs after culture sit together. Even though, in the majority of cultured samples, we detect CD45+ cells associated, similarly to other related publications[27] which reported the benefit of CD45+ (leukocytes) to support CTCs survival [80]. It is well known that the chosen CTC-enrichment approach has some drawbacks as the inefficiency in eliminating leukocyte contamination, resulting in low purity[81]. Hence, finding CD45+ cells in culture initially can be thought as a sign of impurity. However, these cells could be supporting the survival of CTCs *ex vivo*. It has been previously reported how CTCs associated with leukocytes in circulation promotes metastasis[80]. Recently, Xiao et al. have described that cells concomitant with CD45+ cell in short-term culture (30 days) of mBC samples displayed higher growth potential[16]. It would be interesting to characterize in-depth the population of contaminating CD45+ cells to know if they present specific characteristics and to determine if their nature is indeed capable of conditioning the achievement of the culture. However, we had no data regarding concomitant expression of stem cell markers and CD45 after culture since gene expression analysis is performed in a pool of CTCs. It has also been published that the fusion of myeloid cells with CSC promotes metastasis in lung cancer. These hybrid cells escape the immune system and are capable of colonizing distal organs[82]. This phenomenon could be favouring the presence of CD45+ cells in the CTC enriched samples, which would explain its contribution to culture success. Besides, in the same work, Aguirre and colleagues have seen that this fusion depends mainly on the expression of CD36 in CSCs since it is capable of adapting tumor cells to microenvironmental conditions, especially related to energy supply [82]. We have seen an overexpression of CD36 in the CTCs after culture. It has been previously suggested that the addition of lipids and other metabolites to culture media may help the *ex vivo* growth of tumor cells as serum does *in vivo* [44]. Besides, in CSC has been observed metabolic reprogramming[83] since they use mainly fatty acid oxidation and ketone bodies as the main source of energy production. In this work, for the first time, culture media was supplemented with NEs composed of oleic acid and lipids for CTC growth. Thus, the increase in the CD36 fatty acids transporter expression can be associated with the addition of oleic acid to the CTC cultures. Previous work showed that after exogenous addition of oleic acid to breast cancer samples, CD36 expression increased, followed by accumulation of cytoplasmic lipid droplets only in CD36-expressing cells [84]. These findings are in agreement with our previous work where we observed an accumulation of cytoplasmic lipid droplets in breast cancer cells after the addition of NEs, which lead to increased cell viability [45]. In addition, CD36 was already linked with metastatic potential in breast and melanoma cancer metastasis [85] and as a key element of survival in resistant breast cancer cells [86].

Hence, CTCs gene expression before and after culture exhibit a different profile, probably due to the survival of a specific subpopulation with mesenchymal and cancer stem features. The survival and proliferation advantage could have been acquired through evolution from the primary tumor. More interestingly, the ability of CTCs to grow *ex vivo* predicts patient outcome, in terms of PFS. Thus, the CTC population prone to survive and proliferate *in vitro* could reflect the malignancy of CTCs and the patient's state. Previously data from Khoo *et al.* suggested that cultured CTCs can be tools for early prediction of response to therapy. They observed less cell cluster formation in patients with longer treatments, although their data was not statistically significant, probably due to the low number of cases studied (n = 14)[27]. Unexpectedly, our data showed that having ≥ 5 CTCs was not related to PFS nor with successful cultivation. Only 53% of samples were positive for CTCs by Cellsearch® (cut-off of ≥ 5 CTCs) compared with 75% of cultivability in this cohort. It should be noted that the enumeration of CTCs was performed using an epitope-dependent technology (Cellsearch®) that bases its isolation on EpCAM+ cells. For *in vitro* culture we use a negative enrichment approach that isolates all populations of CTC[33]. As both approaches are not comparable, the lack of association may be precisely due to the different subpopulations that could be contributing to the cultivation and its success. Remarkably, the presence of RBCs, evaluated at the beginning of culture, is linked with a worse patient's outcome although it does not influence the success of the culture. Unspecific RBCs isolated in the CTC-enriched fraction were mainly seen in patients

with advanced disease, but not in patients in early stages or healthy donors (data not shown). It has been described that oncologic patients eventually display anaemia and coagulation issues [87–89] but as far as we know, the causes are unknown. The non-specific isolation of RBCs in patients with breast cancer could reflect these imbalances in hematopoietic homeostasis due to bone marrow affection or other alterations derived from the therapy or the general state of these patients.

In this study, there is a limitation due to the lack of pheno- and genotypic characterization of samples. Through immunofluorescence, we can evaluate the co-expression of markers but we have limited the number of genes explored. This is something that we have tried to replace with the gene expression analysis, although it does not offer exhaustive information on how the co-expression of genes is taken place. It is necessary to take into account that once the cells are plated, the manipulation and removal of small amounts for analysis on many occasions conditions its culture continuity. Therefore, characterization was not carried out in each sample included in the study. Besides, CTCs can modify their expression as a consequence of culture conditions (low adherence (3D), addition of growth factors or even the isolation technology used) [62][27].

The short-term culture of CTCs, as well as the presence of RBCs, could be useful tools in the clinic, due to their predictive value of patient's outcome. Since the results are rapid (on day 23rd or immediately, respectively), those patients with positive cultures or the presence of RBCs may require more exhaustive follow-up. Furthermore, CTC culture could also be an intermediate step in the generation of CTC-derived xenograft (CDX) as previously described by our group [90]. Since CD36 is overexpressed in CTCs after culture, they may have a greater potential to generate CDX *in vivo*, taking into account the suggestion that CD36 mediates migration and invasion capacity in breast cancer[91]. However, CDX development shows certain limitations for a direct clinical application due to the long times required for xenographing [92][31]. Nevertheless, our *in vitro* CTC culture protocol offers a simple and less time-consuming compared to *in vivo* models. Thus, these cultures, in their proliferative phase, could be potentially used for drug-testing for personalized oncology and is something to explore in the future.

5. Conclusions

In this work, we have described for the first time the use of NEs to support the cultivation of CTCs from patients. To our knowledge, this is also the first time that the cultivability of CTCs is a predictive factor in mBC. Interestingly, the samples included in this work represents real patients CTCs, adding more value to the study. The analysis of CTCs in culture has also allowed us to study the precursor cells, characterized by presenting mesenchymal and stem features. In addition to culture capacity, the presence of RBCs in culture is also of great relevance. Even so, the potential of CTC functional characterization is not fully understood, as the possibilities of short-term culture are not well-defined.

Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: Gene expression analysis; Figure S2: Survival analysis of alternative samples cohorts. Table S1: Probes of the listed genes for Gene Expression Custom Panel.

Author Contributions: Conceptualization, ABD, CC and RLL; methodology, CA, JC, PP, NCU and MGC.; formal analysis, CC, MGC and NCU; investigation, ABD, CC and NCU; writing—original draft preparation, ABD, CC and NCU; writing—review and editing, ABD, CC, NCU, MGC and JC.; supervision, ABD, CC and RLL.; funding acquisition, RLL. All authors have read and agreed to the published version of the manuscript

Funding: This research was supported by Roche-Chus Joint Unit (IN853B 2018/03), funded by Axencia Galega de Innovación (GAIN), Consellería de Economía, Emprego e Industria. NCU is supported by Axudas Predoutorais do IDIS (Instituto de Investigación Sanitaria de Santiago). MGC is

supported by Instituto de Salud Carlos III (ISCiii), grant FI19/00140, co-financed by the European Regional Development Fund (FEDER).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Galicia approval reference number 2015/772.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Acknowledgements: we would like to thank the patients who had participated in this study. To all the personnel of the Oncology Service at the University Clinical Hospital of Santiago de Compostela, for their help with patient care and sample management; to Laura Muinelo, Alicia Abalo and Ramón Lago-Lestón for technical support. We also thank Montserrat García Lavandeira (Santiago de Compostela University) for her technical assistance with Confocal Microscopy and to Roberto Piñeiro for his criticism and help with the manuscript. The authors would like to thank Servier Medical Art that was used to create the illustrations in Fig. 1.

Conflicts of Interest: R.L.-L. reports grants and personal fees from Roche, Merck, AstraZeneca, Bayer, Pharmamar, Leo, and personal fees and non-financial support from Bristol-Myers Squibb and Novartis, outside of the submitted work. The other authors declare no conflict of interest. A patent entitles "Nanosystems for cellular proliferation" (PCT/EP2018/079214) has been deposited describing the effect of these Nanoemulsions in breast cancer cells.

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* **2021**, *0*, 1–41, doi:10.3322/caac.21660.
2. Redig Metastasis of Cancer. **2013**, *48*, 1–6, doi:10.1111/joim.12084.Breast.
3. Seyfried, T.N.; Huysentruyt, L.C. On the origin of cancer metastasis. *Crit. Rev. Oncog.* **2013**, *18*, 43–73, doi:10.1615/critrevoncog.v18.i1-2.40.
4. Bidard, F.C.; Peeters, D.J.; Fehm, T.; Nolé, F.; Gisbert-Criado, R.; Mavroudis, D.; Grisanti, S.; Generali, D.; Garcia-Saenz, J.A.; Stebbing, J.; et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data. *Lancet Oncol.* **2014**, doi:10.1016/S1470-2045(14)70069-5.
5. De Bono, J.S.; Scher, H.I.; Montgomery, R.B.; Parker, C.; Miller, M.C.; Tissing, H.; Doyle, G. V.; Terstappen, L.W.W.M.; Pienta, K.J.; Raghavan, D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. *Clin. Cancer Res.* **2008**, *14*, 6302–6309, doi:10.1158/1078-0432.CCR-08-0872.
6. Cohen, S.J.; Punt, C.J.A.; Iannotti, N.; Saidman, B.H.; Sabbath, K.D.; Gabrail, N.Y.; Picus, J.; Morse, M.; Mitchell, E.; Miller, M.C.; et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. *J. Clin. Oncol.* **2008**, *26*, 3213–3221, doi:10.1200/JCO.2007.15.8923.
7. Yan, W.T.; Cui, X.; Chen, Q.; Li, Y.F.; Cui, Y.H.; Wang, Y.; Jiang, J. Circulating tumor cell status monitors the treatment responses in breast cancer patients: A meta-analysis. *Sci. Rep.* **2017**, *7*, 1–12, doi:10.1038/srep43464.
8. Alix-Panabières, C.; Bartkowiak, K.; Pantel, K. Functional studies on circulating and disseminated tumor cells in carcinoma patients. *Mol. Oncol.* **2016**, *10*, 443–449, doi:10.1016/j.molonc.2016.01.004.
9. Maheswaran, S.; Haber, D.A. Ex vivo culture of CTCs: An emerging resource to guide cancer therapy. *Cancer Res.* **2015**, *75*, 2411–2415, doi:10.1158/0008-5472.CAN-15-0145.
10. Kowalik, A.; Kowalewska, M.; Gózdź, S. Current approaches for avoiding the limitations of circulating tumor cells detection methods—implications for diagnosis and treatment of patients with solid tumors. *Transl. Res.*

2017.

- 11. Massagué, J.; Obenauf, A.C. Metastatic colonization by circulating tumour cells. *Nature* **2016**, *529*, 298–306, doi:10.1038/nature17038.
- 12. van der Toom, E.E.; Verdone, J.E.; Gorin, M.A.; Pienta, K.J. Technical challenges in the isolation and analysis of circulating tumor cells. *Oncotarget* **2016**.
- 13. Zhang, L.; Ridgway, L.D.; Wetzel, M.D.; Ngo, J.; Yin, W.; Kumar, D.; Goodman, J.C.; Groves, M.D.; Marchetti, D. The identification and characterization of breast cancer CTCs competent for brain metastasis. *Sci. Transl. Med.* **2013**, *5*, 180ra48, doi:10.1126/scitranslmed.3005109.
- 14. Cayrefourcq, L.; Mazard, T.; Jooosse, S.; Solassol, J.; Ramos, J.; Assenat, E.; Schumacher, U.; Costes, V.; Maudelonde, T.; Pantel, K.; et al. Establishment and characterization of a cell line from human Circulating colon cancer cells. *Cancer Res.* **2015**, *75*, 892–901, doi:10.1158/0008-5472.CAN-14-2613.
- 15. Fina, E.; Reduzzi, C.; Motta, R.; Di Cosimo, S.; Bianchi, G.; Martinetti, A.; Wechsler, J.; Cappelletti, V.; Daidone, M.G. Did circulating tumor cells tell us all they could? The missed circulating tumor cell message in breast cancer. *Int. J. Biol. Markers* **2015**, *30*, e429–33, doi:10.5301/jbm.5000166.
- 16. Xiao, J.; McGill, J.R.; Stanton, K.; Kassner, J.D.; Choudhury, S.; Schlegel, R.; Sauna, Z.E.; Pohlmann, P.R.; Agarwal, S. Efficient propagation of circulating tumor cells: A first step for probing tumor metastasis. *Cancers (Basel)* **2020**, *12*, 1–14, doi:10.3390/cancers12102784.
- 17. Bobek, V.; Matkowski, R.; Gürlich, R.; Grabowski, K.; Szelachowska, J.; Lischke, R.; Schützner, J.; Harustiak, T.; Pazdro, A.; Rzechonek, A.; et al. Cultivation of circulating tumor cells in esophageal cancer. *Folia Histochem. Cytobiol.* **2014**, *52*, 171–177, doi:10.5603/FHC.2014.0020.
- 18. Bobek, V.; Kacprzak, G.; Rzechonek, A.; Kolostova, K. Detection and cultivation of circulating tumor cells in malignant pleural mesothelioma. *Anticancer Res.* **2014**, *34*, 2565–2570.
- 19. Kolostova, K.; Matkowski, R.; Gürlich, R.; Grabowski, K.; Soter, K.; Lischke, R.; Schützner, J.; Bobek, V. Detection and cultivation of circulating tumor cells in gastric cancer. *Cytotechnology* **2016**, *68*, 1095–1102, doi:10.1007/s10616-015-9866-9.
- 20. Cegan, M.; Kolostova, K.; Matkowski, R.; Broul, M.; Schraml, J.; Fiutowski, M.; Bobek, V. In vitro culturing of viable circulating tumor cells of urinary bladder cancer. *Int. J. Clin. Exp. Pathol.* **2014**, *7*, 7164–7171.
- 21. Gao, D.; Vela, I.; Sboner, A.; Iaquinta, P.J.; Karthaus, W.R.; Gopalan, A.; Dowling, C.; Wanjala, J.N.; Undvall, E.A.; Arora, V.K.; et al. Organoid cultures derived from patients with advanced prostate cancer. *Cell* **2014**, *159*, 176–187, doi:10.1016/j.cell.2014.08.016.
- 22. Zhang, Z.; Shiratsuchi, H.; Lin, J.; Chen, G.; Reddy, R.M.; Azizi, E.; Fouladdel, S.; Chang, A.C.; Lin, L.; Jiang, H.; et al. Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. *Oncotarget* **2014**, *5*, doi:10.18632/oncotarget.2592.
- 23. Zhang, Z.; Shiratsuchi, H.; Palanisamy, N.; Nagrath, S.; Ramnath, N. Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study. *J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer* **2017**, *12*, 397–402, doi:10.1016/j.jtho.2016.07.027.
- 24. Que, Z.; Luo, B.; Zhou, Z.; Dong, C.; Jiang, Y.; Wang, L.; Shi, Q.; Tian, J. Establishment and characterization of a patient-derived circulating lung tumor cell line in vitro and in vivo. *Cancer Cell Int.* **2019**, *19*, 21, doi:10.1186/s12935-019-0735-z.
- 25. Hamilton, G.; Hochmair, M.; Rath, B.; Klameth, L.; Zeillinger, R. Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype. *Cell Adhes. Migr.* **2016**, *10*, 360–367, doi:10.1080/19336918.2016.1155019.
- 26. Kolostova, K.; Broul, M.; Schraml, J.; Cegan, M.; Matkowski, R.; Fiutowski, M.; Bobek, V. Circulating tumor cells

in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score. *Anticancer Res.* **2014**, *34*, 3641–3646.

27. Khoo, B.L.; Lee, S.C.; Kumar, P.; Tan, T.Z.; Warkiani, M.E.; Ow, S.G.; Nandi, S.; Lim, C.T.; Thiery, J.P. Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. *Oncotarget* **2015**, *6*, doi:10.18632/oncotarget.3903.

28. Yu, M.; Bardia, A.; Aceto, N.; Bersani, F.; Madden, M.W.; Donaldson, M.C.; Desai, R.; Zhu, H.; Comaills, V.; Zheng, Z.; et al. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. *Science (80-.)* **2014**, *345*, 216–220, doi:10.1126/science.1253533.

29. Koch, C.; Kuske, A.; Joosse, S.A.; Yigit, G.; Sfliomos, G.; Thaler, S.; Smit, D.J.; Werner, S.; Borgmann, K.; Gärtnner, S.; et al. Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. *EMBO Mol. Med.* **2020**, *12*, 1–22, doi:10.15252/emmm.201911908.

30. Sheng, W.; Ogunwobi, O.O.; Chen, T.; Zhang, J.; George, T.J.; Liu, C.; Fan, Z.H. Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. *Lab Chip* **2014**, *14*, 89–98, doi:10.1039/c3lc51017d.

31. Brungs, D.; Minaei, E.; Piper, A.K.; Perry, J.; Splitt, A.; Carolan, M.; Ryan, S.; Wu, X.J.; Corde, S.; Tehei, M.; et al. Establishment of novel long-term cultures from EpCAM positive and negative circulating tumour cells from patients with metastatic gastroesophageal cancer. *Sci. Rep.* **2020**, *10*, 1–13, doi:10.1038/s41598-019-57164-6.

32. Soler, A.; Cayrefourcq, L.; Mazard, T.; Babayan, A.; Lamy, P.J.; Assou, S.; Assenat, E.; Pantel, K.; Alix-Panabières, C. Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes. *Sci. Rep.* **2018**, *8*, 1–12, doi:10.1038/s41598-018-34365-z.

33. Tellez-Gabriel, M.; Cochonneau, D.; Cadé, M.; Jubellin, C.; Heymann, M.-F.; Heymann, D. Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine. *Cancers (Basel)* **2018**, *11*, doi:10.3390/cancers11010019.

34. Duval, K.; Grover, H.; Han, L.-H.; Mou, Y.; Pegoraro, A.F.; Fredberg, J.; Chen, Z. Modeling Physiological Events in 2D vs. 3D Cell Culture. *Physiology (Bethesda)* **2017**, *32*, 266–277, doi:10.1152/physiol.00036.2016.

35. Hoarau-Véchot, J.; Rafii, A.; Touboul, C.; Pasquier, J. Halfway between 2D and Animal Models: Are 3D Cultures the Ideal Tool to Study Cancer-Microenvironment Interactions? *Int. J. Mol. Sci.* **2018**, *19*, doi:10.3390/ijms19010181.

36. Kapałczyńska, M.; Kolenda, T.; Przybyła, W.; Zajączkowska, M.; Teresiak, A.; Filas, V.; Ibbs, M.; Bliźniak, R.; Łuczewski, Ł.; Lamperska, K. 2D and 3D cell cultures – a comparison of different types of cancer cell cultures. *Arch. Med. Sci.* **2018**, *14*, 910–919, doi:10.5114/aoms.2016.63743.

37. Nath, S.; Devi, G.R. Three-dimensional culture systems in cancer research: Focus on tumor spheroid model. *Pharmacol. Ther.* **2016**, *163*, 94–108, doi:10.1016/j.pharmthera.2016.03.013.

38. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. *Proc. Natl. Acad. Sci. U. S. A.* **2003**, *100*, 3983–3988, doi:10.1073/pnas.0530291100.

39. Tosoni, D.; Di Fiore, P.P.; Pece, S. Functional purification of human and mouse mammary stem cells. *Methods Mol. Biol.* **2012**, *916*, 59–79, doi:10.1007/978-1-61779-980-8_6.

40. Zhang, Y.; Zhang, X.; Zhang, J.; Sun, B.; Zheng, L.; Li, J.; Liu, S.; Sui, G.; Yin, Z. Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay. *Cancer Biol. Ther.* **2016**, *17*, 1177–1187, doi:10.1080/15384047.2016.1235665.

41. Klameth, L.; Rath, B.; Hochmaier, M.; Moser, D.; Redl, M.; Mungenast, F.; Gelles, K.; Ulsperger, E.; Zeillinger, R.; Hamilton, G. Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance. *Sci. Rep.* **2017**, *7*, 5337, doi:10.1038/s41598-017-05562-z.

42. Vishnoi, M.; Peddibhotla, S.; Yin, W.; Scamardo, A.T.; George, G.C.; Hong, D.S.; Marchetti, D. The isolation and

characterization of CTC subsets related to breast cancer dormancy. *Sci. Rep.* **2015**, *5*, 1–14, doi:10.1038/srep17533.

43. Soeda, A.; Park, M.; Lee, D.; Mintz, A.; Androutsellis-Theotokis, A.; McKay, R.D.; Engh, J.; Iwama, T.; Kunisada, T.; Kassam, A.B.; et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. *Oncogene* **2009**, *28*, 3949–3959, doi:10.1038/onc.2009.252.

44. Ackermann, T.; Tardito, S. Cell Culture Medium Formulation and Its Implications in Cancer Metabolism. *Trends in Cancer* **2019**, *5*, 329–332, doi:10.1016/j.trecan.2019.05.004.

45. Carmona-Ule, N.; Abuín-Redondo, C.; Costa, C.; Piñeiro, R.; Pereira-Veiga, T.; Martínez-Pena, I.; Hurtado, P.; López-López, R.; de la Fuente, M.; Dávila-Ibáñez, A.B. Corrigendum to “Nanoemulsions to support ex vivo cell culture of breast cancer circulating tumor cells” [Materials Today Chemistry 16 (2020) 100265] (Materials Today Chemistry (2020) 16, (S2468519420300252), (10.1016/j.mtchem.2020.100265)). *Mater. Today Chem.* **2020**, *18*, 100370, doi:10.1016/j.mtchem.2020.100370.

46. Avagliano, A.; Ruocco, M.R.; Aliotta, F.; Belviso, I.; Accurso, A.; Masone, S.; Montagnani, S.; Arcucci, A. Mitochondrial Flexibility of Breast Cancers: A Growth Advantage and a Therapeutic Opportunity. *Cells* **2019**, *8*, 401, doi:10.3390/cells8050401.

47. Nath, A.; Chan, C. Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers. *Sci. Rep.* **2016**, *6*, 18669, doi:10.1038/srep18669.

48. Antalis, C.J.; Uchida, A.; Buhman, K.K.; Siddiqui, R.A. Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification. *Clin. Exp. Metastasis* **2011**, *28*, 733–741, doi:10.1007/s10585-011-9405-9.

49. Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* **2012**, *9*, 671–675, doi:10.1038/nmeth.2089.

50. Che, J.; Yu, V.; Dhar, M.; Renier, C.; Matsumoto, M.; Heirich, K.; Garon, E.B.; Goldman, J.; Rao, J.; Sledge, G.W.; et al. Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology. *Oncotarget* **2016**, *7*, 12748–12760, doi:10.18632/oncotarget.7220.

51. Oeyen, S.; Liégeois, V.; De Laere, B.; Buys, A.; Strijbos, M.; Dirix, P.; Meijnders, P.; Vermeulen, P.; Van Laere, S.; Dirix, L. Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer. *Prostate Cancer Prostatic Dis.* **2020**, doi:10.1038/s41391-020-00304-1.

52. Toss, A.; Mu, Z.; Fernandez, S.; Cristofanilli, M. CTC enumeration and characterization: moving toward personalized medicine. *Ann. Transl. Med.* **2014**, *2*, 108, doi:10.3978/j.issn.2305-5839.2014.09.06.

53. D'Oronzo, S.; Lovero, D.; Palmirotta, R.; Stucci, L.S.; Tucci, M.; Felici, C.; Cascardi, E.; Giardina, C.; Cafforio, P.; Silvestris, F. Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer. *Sci. Rep.* **2019**, *9*, 1–13, doi:10.1038/s41598-019-53660-x.

54. Kulasinghe, A.; Kapeleris, J.; Cooper, C.; Warkiani, M.E.; O'Byrne, K.; Punyadeera, C. Phenotypic characterization of circulating lung cancer cells for clinically actionable targets. *Cancers (Basel)* **2019**, *11*, 1–13, doi:10.3390/cancers11030380.

55. Tayoun, T.; Faugeron, V.; Oulhen, M.; Aberlenc, A.; Pawlikowska, P.; Farace, F. CTC-Derived Models: A Window into the Seeding Capacity of Circulating Tumor Cells (CTCs). *Cells* **2019**, *8*, 1–17, doi:10.3390/cells8101145.

56. Sharma, S.; Zhuang, R.; Long, M.; Pavlovic, M.; Kang, Y.; Ilyas, A.; Asghar, W. Circulating tumor cell isolation, culture, and downstream molecular analysis. *Biotechnol. Adv.* **2018**.

57. Luo, X.; Zhao, X.; Cheng, C.; Li, N.; Liu, Y.; Cao, Y. The implications of signaling lipids in cancer metastasis. *Exp. Mol. Med.* **2018**, *50*, doi:10.1038/s12276-018-0150-x.

58. Monaco, M.E. Fatty acid metabolism in breast cancer subtypes. *Oncotarget* **2017**, *8*, 29487–29500,

doi:10.18632/oncotarget.15494.

59. Xu, S.; Chen, T.; Dong, L.; Li, T.; Xue, H.; Gao, B.; Ding, X.; Wang, H.; Li, H. Fatty acid synthase promotes breast cancer metastasis by mediating changes in fatty acid metabolism. *Oncol. Lett.* **2021**, *21*, 1–9, doi:10.3892/ol.2020.12288.

60. Kulasinghe, A.; Perry, C.; Warkiani, M.E.; Blick, T.; Davies, A.; O'Byrne, K.; Thompson, E.W.; Nelson, C.C.; Vela, I.; Punyadeera, C. Short term ex-vivo expansion of circulating head and neck tumour cells. *Oncotarget* **2016**, *7*, 60101–60109, doi:10.18632/oncotarget.11159.

61. Kapeleris, J.; Kulasinghe, A.; Warkiani, M.E.; Oleary, C.; Vela, I.; Leo, P.; Sternes, P.; O'Byrne, K.; Punyadeera, C. Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer. *Transl. Lung Cancer Res.* **2020**, *9*, 1795–1809, doi:10.21037/tlcr-20-521.

62. Wang, R.; Chu, G.C.Y.; Mrdenovic, S.; Annamalai, A.A.; Hendifar, A.E.; Nissen, N.N.; Tomlinson, J.S.; Lewis, M.; Palanisamy, N.; Tseng, H.-R.; et al. Cultured circulating tumor cells and their derived xenografts for personalized oncology. *Asian J. Urol.* **2016**, *3*, 240–253, doi:10.1016/j.ajur.2016.08.005.

63. Ginestier, C.; Hur, M.H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C.G.; Liu, S.; et al. ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. *Cell Stem Cell* **2007**, *1*, 555–567, doi:10.1016/j.stem.2007.08.014.

64. Xin, Y.; Li, K.; Yang, M.; Tan, Y. Fluid shear stress induces emt of circulating tumor cells via jnk signaling in favor of their survival during hematogenous dissemination. *Int. J. Mol. Sci.* **2020**, *21*, 1–16, doi:10.3390/ijms21218115.

65. Peake, B.F.; Eze, S.M.; Yang, L.; Castellino, R.C.; Nahta, R. Erratum: Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling (Oncotarget (2017) 8 (94393–94406) DOI: 10.18632/oncotarget.21765). *Oncotarget* **2020**, *11*, 4074–4075, doi:10.18632/oncotarget.27779.

66. Modi, A.; Dwivedi, S.; Roy, D.; Khokhar, M.; Purohit, P.; Vishnoi, J.; Pareek, P.; Sharma, S.; Sharma, P.; Misra, S. Growth differentiation factor 15 and its role in carcinogenesis: an update. *Growth Factors* **2019**, *37*, 190–207, doi:10.1080/08977194.2019.1685988.

67. Tanabe, S.; Kawabata, T.; Aoyagi, K.; Yokozaki, H.; Sasaki, H. Gene expression and pathway analysis of CTNNB1 in cancer and stem cells. *World J. Stem Cells* **2016**, *8*, 384–395, doi:10.4252/wjsc.v8.i11.384.

68. Lin, S.Y.; Chang, S.-C.; Lam, S.; Irene Ramos, R.; Tran, K.; Ohe, S.; Salomon, M.P.; Bhagat, A.A.S.; Teck Lim, C.; Fischer, T.D.; et al. Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy. *Clin. Chem.* **2020**, *66*, 169–177, doi:10.1373/clinchem.2019.307140.

69. Zhu, L.; Hissa, B.; Győrffy, B.; Jann, J.-C.; Yang, C.; Reissfelder, C.; Schölch, S. Characterization of Stem-like Circulating Tumor Cells in Pancreatic Cancer. *Diagnostics (Basel, Switzerland)* **2020**, *10*, doi:10.3390/diagnostics10050305.

70. Li, L.; Li, W. Epithelial-mesenchymal transition in human cancer: Comprehensive reprogramming of metabolism, epigenetics, and differentiation. *Pharmacol. Ther.* **2015**, *150*, 33–46, doi:10.1016/j.pharmthera.2015.01.004.

71. Morel, A.P.; Lièvre, M.; Thomas, C.; Hinkal, G.; Ansieau, S.; Puisieux, A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. *PLoS One* **2008**, *3*, 1–7, doi:10.1371/journal.pone.0002888.

72. Wilson, M.M.; Weinberg, R.A.; Lees, J.A.; Guen, V.J. Emerging Mechanisms by which EMT Programs Control Stemness. *Trends in Cancer* **2020**, *6*, 775–780, doi:10.1016/j.trecan.2020.03.011.

73. Pereira-Veiga, T.; Martínez-Fernández, M.; Abuin, C.; Piñeiro, R.; Cebey, V.; Cueva, J.; Palacios, P.; Blanco, C.; Muinelo-Romay, L.; Abalo, A.; et al. CTCs Expression Profiling for Advanced Breast Cancer Monitoring. *Cancers (Basel)* **2019**, *11*, doi:10.3390/cancers11121941.

74. Reduzzi, C.; Vismara, M.; Gerratana, L.; Silvestri, M.; De Braud, F.; Raspagliesi, F.; Verzoni, E.; Di Cosimo, S.;

Locati, L.D.; Cristofanilli, M.; et al. The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. *Semin. Cancer Biol.* **2019**, *0*–1, doi:10.1016/j.semcaner.2019.10.008.

75. Domingos Chinen, L.T.; Lopes Mello, C.A.; Abdallah, E.A.; Ocea, L.M.M.; Buim, M.E.; Breve, N.M.; Gasparini, J.L.; Fanelli, M.F.; Paterlini-Bréchot, P. Isolation, Detection, And immunomorphological characterization of circulating tumor cells (CTCs) from patients with different types of sarcoma using isolation by size of tumor cells: A window on sarcoma-cell invasion. *Onco. Targets. Ther.* **2014**, *7*, 1609–1617, doi:10.2147/OTT.S62349.

76. Emerson, T.; Kirby, M.; Bethel, K.; Kolatkar, A.; Luttgen, M.; O'Hara, S.; Newton, P.; Kuhn, P. Fourier-ring descriptor to characterize rare circulating cells from images generated using immunofluorescence microscopy. *Comput. Med. imaging Graph. Off. J. Comput. Med. Imaging Soc.* **2015**, *40*, 70–87, doi:10.1016/j.compmedimag.2014.10.003.

77. Lazar, D.C.; Cho, E.H.; Luttgen, M.S.; Metzner, T.J.; Uson, M.L.; Torrey, M.; Gross, M.E.; Kuhn, P. Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line. *Phys. Biol.* **2012**, *9*, 16002, doi:10.1088/1478-3975/9/1/016002.

78. Boshuizen, R.; Kuhn, P.; van den Heuvel, M. Circulating tumor cells in non-small cell lung carcinoma. *J. Thorac. Dis.* **2012**, *4*, 456–458, doi:10.3978/j.issn.2072-1439.2012.08.21.

79. Adams, D.L.; Martin, S.S.; Alpaugh, R.K.; Charpentier, M.; Tsai, S.; Bergan, R.C.; Ogden, I.M.; Catalona, W.; Chumsri, S.; Tang, C.-M.; et al. Circulating giant macrophages as a potential biomarker of solid tumors. *Proc. Natl. Acad. Sci. U. S. A.* **2014**, *111*, 3514–3519, doi:10.1073/pnas.1320198111.

80. Cools-Lartigue, J.; Spicer, J.; McDonald, B.; Gowing, S.; Chow, S.; Giannias, B.; Bourdeau, F.; Kubes, P.; Ferri, L. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. *J. Clin. Invest.* **2013**, *123*, 3446–3458, doi:10.1172/JCI67484.

81. Kang, Q.; Henry, N.L.; Paoletti, C.; Jiang, H.; Vats, P.; Chinnaian, A.M.; Hayes, D.F.; Merajver, S.D.; Rae, J.M.; Tewari, M. Comparative analysis of circulating tumor DNA stability In K(3)EDTA, Streck, and CellSave blood collection tubes. *Clin. Biochem.* **2016**, *49*, 1354–1360, doi:10.1016/j.clinbiochem.2016.03.012.

82. Aguirre, L.A.; Montalbán-Hernández, K.; Avendaño-Ortiz, J.; Marín, E.; Lozano, R.; Toledano, V.; Sánchez-Maroto, L.; Terrón, V.; Valentín, J.; Pulido, E.; et al. Tumor stem cells fuse with monocytes to form highly invasive tumor-hybrid cells. *Oncoimmunology* **2020**, *9*, 1–17, doi:10.1080/2162402X.2020.1773204.

83. Yadav, U.P.; Singh, T.; Kumar, P.; Sharma, P.; Kaur, H.; Sharma, S.; Singh, S.; Kumar, S.; Mehta, K. Metabolic Adaptations in Cancer Stem Cells. *Front. Oncol.* **2020**, *10*, 1010.

84. Zhao, J.; Zhi, Z.; Wang, C.; Xing, H.; Song, G.; Yu, X.; Zhu, Y.; Wang, X.; Zhang, X.; Di, Y. Exogenous lipids promote the growth of breast cancer cells via CD36. *Oncol. Rep.* **2017**, *38*, 2105–2115, doi:10.3892/or.2017.5864.

85. Pascual, G.; Avgustinova, A.; Mejetta, S.; Martín, M.; Castellanos, A.; Attolini, C.S.-O.; Berenguer, A.; Prats, N.; Toll, A.; Hueto, J.A.; et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. *Nature* **2017**, *541*, 41–45, doi:10.1038/nature20791.

86. Feng, W.W.; Wilkins, O.; Bang, S.; Ung, M.; Li, J.; An, J.; del Genio, C.; Canfield, K.; DiRenzo, J.; Wells, W.; et al. CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies. *Cell Rep.* **2019**, *29*, 3405–3420.e5, doi:https://doi.org/10.1016/j.celrep.2019.11.008.

87. Dicato, M.; Plawny, L.; Diederich, M. Anemia in cancer. *Ann. Oncol.* **2010**, *21*, vii167–vii172, doi:10.1093/annonc/mdq284.

88. Lang, E.; Bissinger, R.; Qadri, S.M.; Lang, F. Suicidal death of erythrocytes in cancer and its chemotherapy: A potential target in the treatment of tumor-associated anemia. *Int. J. cancer* **2017**, *141*, 1522–1528, doi:10.1002/ijc.30800.

89. Lominadze, D.; Dean, W.L. Involvement of fibrinogen specific binding in erythrocyte aggregation. *FEBS Lett.* **2002**, *517*, 41–44, doi:10.1016/S0014-5793(02)02575-9.

90. Pereira-Veiga, T.; Abreu, M.; Robledo, D.; Matias-Guiu, X.; Santacana, M.; Sanchez, L.; Cueva, J.; Palacios, P.; Abdulkader, I.; Lopez-Lopez, R.; et al. CTCs-derived xenograft development in a triple negative breast cancer case. *Int. J. cancer* **2018**, doi:10.1002/ijc.32001.
91. Liang, Y.; Han, H.; Liu, L.; Duan, Y.; Yang, X.; Ma, C.; Zhu, Y.; Han, J.; Li, X.; Chen, Y. CD36 plays a critical role in proliferation, migration and tamoxifen-inhibited growth of ER-positive breast cancer cells. *Oncogenesis* **2018**, 7, 98, doi:10.1038/s41389-018-0107-x.
92. Lallo, A.; Schenk, M.W.; Frese, K.K.; Blackhall, F.; Dive, C. Circulating tumor cells and CDX models as a tool for preclinical drug development. *Transl. Lung Cancer Res.* **2017**, 6, 397–408, doi:10.21037/tlcr.2017.08.01.